Subscribe
pimpic-shutterstock-com
pimpic / Shutterstock.com
18 April 2016Asia

Indian drug makers end generic bids

Indian-based drugs companies BDR Pharmaceutical and Lee Pharmaceutical have reportedly abandoned their attempt to produce generic versions of two drugs developed by AstraZeneca and Bristol-Myers Squibb (BMS).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
MSF urges Indian Patent Office to reject Gilead Sovaldi patent
2 March 2016   Médecins Sans Frontières has urged the Indian Patent Office to reject a Gilead Sciences patent application covering Sovaldi.
Asia
India should remain on 301 ‘Priority Watch List’, says PhRMA
9 February 2016   India’s weak intellectual property enforcement regime and its vague grounds centring on compulsory licences for drugs are reasons it should remain on the “Priority Watch List” in this year’s "Special 301 Report", a pharmaceutical industry association has argued.
Asia
Indian Pharmaceutical Alliance drops Sovaldi opposition
16 September 2015   The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Asia
MSF urges Indian Patent Office to reject Gilead Sovaldi patent
2 March 2016   Médecins Sans Frontières has urged the Indian Patent Office to reject a Gilead Sciences patent application covering Sovaldi.
Asia
India should remain on 301 ‘Priority Watch List’, says PhRMA
9 February 2016   India’s weak intellectual property enforcement regime and its vague grounds centring on compulsory licences for drugs are reasons it should remain on the “Priority Watch List” in this year’s "Special 301 Report", a pharmaceutical industry association has argued.
Asia
Indian Pharmaceutical Alliance drops Sovaldi opposition
16 September 2015   The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.

More on this story

Asia
MSF urges Indian Patent Office to reject Gilead Sovaldi patent
2 March 2016   Médecins Sans Frontières has urged the Indian Patent Office to reject a Gilead Sciences patent application covering Sovaldi.
Asia
India should remain on 301 ‘Priority Watch List’, says PhRMA
9 February 2016   India’s weak intellectual property enforcement regime and its vague grounds centring on compulsory licences for drugs are reasons it should remain on the “Priority Watch List” in this year’s "Special 301 Report", a pharmaceutical industry association has argued.
Asia
Indian Pharmaceutical Alliance drops Sovaldi opposition
16 September 2015   The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility